

ABSTRACT

The present invention relates the use of  $\alpha_{1A}$  and/or  $\alpha_{1L}$  adrenergic receptor antagonists for the treatment of female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD) and/or female orgasmic disorder (FOD). The present  
5 invention also relates to a method of treatment of FSD, in particular FSAD and/or FOD, as well as to assays to screen for compounds useful in the treatment of FSD, in particular FSAD and/or FOD.